Programme
Monday 24 January
09:05 - 09:25 |
Nisha Sharma
Minimally invasive techniques for therapeutic treatment of cancers
09:25 - 09:45 |
Charlotte Coles
Risk-adapted tailored breast radiotherapy: one size no longer fits all
09:45 - 10:05 |
Amit Goyal
Risk-adapted axillary surgery including TAD and its practical aspects
10:05 - 10:25 |
Alastair M Thompson
What's new in DCIS: A grand challenge
10:25 - 10:45 |
Panel discussion
11:15 - 11:35 |
Mitch Dowsett
Pre-surgical provocation tests for clinical trials and management
11:35 - 11:55 |
Nadia Harbeck
Are CDK 4/6 inhibitors ready for clinical use?
11:55 - 12:15 |
Andrew Tutt
Optimising systemic therapy for women with BRCA mutations: Current knowledge and future directions
12:15 - 12:35 |
Iain Macpherson
Neoadjuvant anti-HER2 therapy enabled risk adaptation: An era to optimise practice
12:35 - 12:55 |
Panel discussion
13:40 - 14:00 |
Lucy Yates
Molecular evolution of breast cancer
14:00 - 14:20 |
Fiona Gilbert
Personalised breast cancer screening
14:20 - 14:40 |
Douglas Easton
Past, present and future directions in breast cancer genetics
14:40 - 15:00 |
Kelly-Anne Phillips
Strategies to prevent breast cancer
15:00 - 15:20 |
Panel discussion
15:45 - 16:05 |
Fabrice André
Should we be offering next generation sequencing for routine clinical use?
16:05 - 16:25 |
Peter Schmid
Immunotherapy for metastatic breast cancer
16:25 - 16:45 |
Stephen Johnston
Optimal management and treatment sequencing of ER+ HER2- metastatic breast cancer
16:45 - 17:05 |
Nita Nair
Role of surgery in metastatic breast cancer
17:05 - 17:25 |
Panel discussion
18:00 - 19:00 |
Gilead industry symposium
Tuesday 25 January
07:45 - 08:45 |
Sanofi industry symposium
09:15 - 09:40 |
Henrik Ditzel
Co-targeting CDK4/6 and AKT with endocrine therapy overcomes CDK4/6 inhibitor and endocrine therapy resistance in preclinical breast cancer models
09:40 - 10:05 |
Georgia Mavria
The challenge of modelling of brain metastases - combining in vivo, cell culture and organotypic approaches to investigate brain extravasation
10:05 - 10:30 |
Seth Coffelt
The role of gamma delta T cells in breast cancer development/metastasis
10:30 - 10:55 |
Use of single cell sequencing in breast cancer research - opportunities and pitfalls
11:25 - 11:50 |
Janet Dunn
Unmet need and follow-up
11:50 - 12:15 |
Jane Murphy
Breast Cancer Now's Helpline and patient focused resources
12:15 - 12:40 |
Adherence/real world data
12:40 - 13:05 |
Linda Sharp
Supporting women with adherence to endocrine therapy following breast cancer: the SWEET programme
13:50 - 14:00 |
Dame Cally Palmer
Future of cancer services in the UK
14:00 - 14:10 |
Dr Raghavan Vidya MS, MD, FRCS
Future vision for breast surgery
14:10 - 14:20 |
Imogen Locke
Future vision for radiotherapy
14:20 - 14:30 |
Sarah Pinder
Future vision for pathology
14:30 - 14:40 |
Sarah Vinnicombe
Future vision for radiology
14:40 - 14:50 |
Judith Bliss
Future vision for clinical trials
14:50 - 15:30 |
Panel discussion
16:00 - 17:00 |
Lilly symposium
17:30 - 18:00 |